AcuCort (ACUC) investor relations material

Executive summary

• Achieved key regulatory milestones, including FDA agreement on iPSP and Small Business Waiver, paving the way for NDA submission in the US during 2026.

• Signed a commercial partnership with Glenmark Pharmaceuticals for six European countries, with launches planned for 2027.

• Zeqmelit® launched in the Nordic region, with growing international interest and ongoing discussions for further partnerships.

• Delivered on strategic goals, strengthening organizational capabilities and preparing for US market entry.

Financial highlights

• Net sales for Q2 2026 were 1,158 KSEK, up from 162 KSEK in Q2 2025; H1 2026 net sales also 1,158 KSEK.

• Net loss after tax for Q2 2026 was -8,201 KSEK (Q2 2025: -7,569 KSEK); H1 2026 net loss was -15,034 KSEK (H1 2025: -14,093 KSEK).

• Earnings per share for Q2 2026 were -0.03 SEK (Q2 2025: -0.04 SEK); H1 2026 EPS was -0.06 SEK (H1 2025: -0.07 SEK).

• Cash and cash equivalents at period end were 10,374 KSEK, down from 27,012 KSEK at year-end 2025.

Outlook and guidance

• Expects further regulatory approvals outside the Nordics and increased sales as Zeqmelit® becomes more established.

• Glenmark partnership expected to generate revenue after market approvals, with launches in six European countries planned for 2027.

• Plans to expand into additional European markets, the US, and other key markets, anticipating further revenue growth.